-

Galderma Publishes its 2024 Annual Report and the Invitation to Its First Annual General Meeting

Ad hoc announcement pursuant to Art. 53 LR

ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published its 2024 Annual Report along with the invitation to its first Annual General Meeting which will be held on April 23, 2025.

Galderma’s 2024 Annual Report, the 2024 Finance Report and the invitation to the Annual General Meeting are available on Galderma’s Investor Relations website at https://investors.galderma.com/.

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

Contacts

For further information:

Media
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Sébastien Cros
Corporate Communications Director
sebastien.cros@galderma.com
+41 79 529 59 85

Investors
Emil Ivanov
Head of Strategy, Investor Relations and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

Industry:

Galderma Group AG

SWX:GALD
Release Versions
English

Contacts

For further information:

Media
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Sébastien Cros
Corporate Communications Director
sebastien.cros@galderma.com
+41 79 529 59 85

Investors
Emil Ivanov
Head of Strategy, Investor Relations and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

More News From Galderma Group AG

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This milestone represents yet another example of Galderma’s unique Integrated Dermatology stra...

Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency

ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,...

Galderma Shareholders Approve All Annual General Meeting Proposals

ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), held earlier today via live webcast. This includes the payment of a gross dividend of 0.35 CHF per dividend-bearing share1, to be distributed out of reserves from capital contributions. Shareholders approved the election of Harry Kirsch as independent member of the...
Back to Newsroom